Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
- PMID: 24646493
- PMCID: PMC3995113
- DOI: 10.1186/1756-8722-7-25
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
Abstract
Background: Myeloproliferative neoplasms (MPNs) are blood malignancies manifested in increased production of red blood cells, white blood cells, and/or platelets. A major molecular lesion associated with the diseases is JAK2V617F, an activation mutation form of tyrosine kinase JAK2. Cardiovascular events represent the leading cause of morbidity and mortality associated MPNs, but the underlying mechanism is not well understood.
Methods: Previously, we generated JAK2V617F transgenic mice which displayed MPN-like phenotypes. In the present study, we further characterized these mice by analyzing the time course of MPN phenotype development and associated cardiac abnormalities. We performed detailed histochemical staining of cardiac sections.
Results: JAK2V617F transgenic mice developed cardiomegaly as a subsequent event of increased blood cell production during the course of MPN phenotype development. The cardiomegaly is manifested in increased ventricular wall thickness and enlarged cardiomyocytes. Trichrome and reticulin staining revealed extensive collagen fibrosis in the heart of JAK2V617F transgenic mice. Thrombosis in the coronary artery and inflammatory cell infiltration into cardiac muscle were also observed in JAK2V617F transgenic mice, and the latter event was accompanied by fibrosis.
Conclusion: JAK2V617F-induced blood disorders have a major impact on heart function and lead to cardiac hypertrophy. JAK2V617F transgenic mice represent an excellent model system to study both hematological malignancies and cardiovascular diseases.
Figures
Similar articles
-
Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):374-81. doi: 10.1177/1076029612453761. Epub 2012 Jul 23. Clin Appl Thromb Hemost. 2013. PMID: 22826442 Review.
-
Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.J Clin Invest. 2018 Jan 2;128(1):125-140. doi: 10.1172/JCI94518. Epub 2017 Nov 20. J Clin Invest. 2018. PMID: 29202466 Free PMC article.
-
Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.J Thromb Haemost. 2020 Dec;18(12):3359-3370. doi: 10.1111/jth.15095. Epub 2020 Oct 5. J Thromb Haemost. 2020. PMID: 32920974 Free PMC article.
-
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.Blood. 2013 May 2;121(18):3692-702. doi: 10.1182/blood-2012-05-432989. Epub 2013 Mar 13. Blood. 2013. PMID: 23487027 Free PMC article.
-
Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Curr Protoc Pharmacol. 2017 Jun 22;77:14.40.1-14.40.19. doi: 10.1002/cpph.23. Curr Protoc Pharmacol. 2017. PMID: 28640953 Free PMC article. Review.
Cited by
-
Adipose Stem Cell-Seeded Decellularized Porcine Pericardium: A Promising Functional Biomaterial to Synergistically Restore the Cardiac Functions Post-Myocardial Infarction.Vet Sci. 2023 Nov 17;10(11):660. doi: 10.3390/vetsci10110660. Vet Sci. 2023. PMID: 37999483 Free PMC article.
-
Effect of trehalose on heart functions in rats model after myocardial infarction: assessment of novel intraventricular pressure and heart rate variability.Front Cardiovasc Med. 2023 Jun 21;10:1182628. doi: 10.3389/fcvm.2023.1182628. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37469485 Free PMC article.
-
Changes in Cardiac Function During the Development of Uremic Cardiomyopathy and the Effect of Salvianolic Acid B Administration in a Rat Model.Front Vet Sci. 2022 Jun 16;9:905759. doi: 10.3389/fvets.2022.905759. eCollection 2022. Front Vet Sci. 2022. PMID: 35782566 Free PMC article.
-
A One-Stop Protocol to Assess Myocardial Fibrosis in Frozen and Paraffin Sections.Methods Protoc. 2022 Jan 27;5(1):13. doi: 10.3390/mps5010013. Methods Protoc. 2022. PMID: 35200529 Free PMC article.
-
Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.Leukemia. 2021 Apr;35(4):935-955. doi: 10.1038/s41375-021-01170-z. Epub 2021 Mar 3. Leukemia. 2021. PMID: 33658660 Review.
References
-
- Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol. 2010;85:62–69. - PubMed
-
- Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–1097. doi: 10.1182/blood-2007-04-083501. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
